

Whitaker's core insight: Short-term efficacy doesn't predict long-term benefit. The Harrow Study (20-year naturalistic follow-up) found schizophrenia patients not continuously on antipsychotics after year two showed better recovery rates, lower rehospitalisation, and better work functioning. Chronic medication may create dopamine supersensitivity psychosis—brain adaptations that worsen underlying conditions.

Outcome depends entirely on field conditions: whether consciousness encounters dissolution with conceptual framework, capacity to surrender, support structure, and clear return pathway—or faces the void alone, terrified, and fragmented.



